BenchSci logo
Verified via Expert Interviews

BenchSci: Revenue, Valuation & Competitors

BenchSci company overview

Ownership
PE-backed
Employees
369
Investors
Generation Investment Management
Revenue / FTE
$6•k

About

Disease biology AI platform for pharmaceutical and biotechnology R&D teams to accelerate preclinical drug discovery and improve experimental success rates.
Canada
Verified via Expert Interviews

Expert Vetted Data

Public disclosures rarely capture a company's internal dynamics or the true state of its technology. Gain first-hand insight by speaking with former BenchSci executives.

Ownership & Key Financials

Revenue

$2•m '••
1

Investors

Generation Investment Management
'23

Revenue / FTE

$6•k '••
1

Ownership

PE-backed

FTEs

1
+37% CAGR
140
2020
221
2021
378
2022
435
2023
369
2024

Legal Disclaimer

The company profiles displayed here are abridged, indicative previews of the full, proprietary data available within the Dialectica Origin Platform, derived from confidential sources and expert-vetted research. This content is the exclusive Intellectual Property (IP) of Dialectica. Your access does not grant any rights to the data. Systematic copying, scraping, crawling, indexing, or extraction, whether by manual means, automated software, bots, or Large Language Models (LLMs), is strictly prohibited and violates our Terms of Use.

This information is provided 'as is' for promotional purposes only; Dialectica disclaims all liability for its accuracy, completeness, or any reliance placed upon it.